Search results
Showing 2656 to 2670 of 8929 results
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Awaiting development Reference number: GID-TA11968 Expected publication date: TBC
In development Reference number: GID-TA10239 Expected publication date: 06 August 2026
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)
Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making